↓ Skip to main content

Michigan Publishing

Modelling the cost-effectiveness of pay-for-performance in primary care in the UK

Overview of attention for article published in BMC Medicine, August 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
63 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
105 Mendeley
Title
Modelling the cost-effectiveness of pay-for-performance in primary care in the UK
Published in
BMC Medicine, August 2018
DOI 10.1186/s12916-018-1126-3
Pubmed ID
Authors

Ankur Pandya, Tim Doran, Jinyi Zhu, Simon Walker, Emily Arntson, Andrew M. Ryan

Abstract

Introduced in 2004, the United Kingdom's (UK) Quality and Outcomes Framework (QOF) is the world's largest primary-care pay-for-performance programme. Given some evidence of the benefits and the substantial costs associated with the QOF, it remains unclear whether the programme is cost-effective. Therefore, we assessed the cost-effectiveness of continuing versus stopping the QOF. We developed a lifetime simulation model to estimate quality-adjusted life years (QALYs) and costs for a UK population cohort aged 40-74 years (n = 27,070,862) exposed to the QOF and for a counterfactual scenario without exposure. Based on a previous retrospective cross-country analysis using data from 1994 to 2010, we assumed the benefits of the QOF to be a change in age-adjusted mortality of -3.68 per 100,000 population (95% confidence interval -8.16 to 0.80). We used cost-effectiveness thresholds of £30,000/QALY, £20,000/QALY and £13,000/QALY to determine the optimal strategy in base-case and sensitivity analyses. In the base-case analysis, continuing the QOF increased population-level QALYs and health-care costs yielding an incremental cost-effectiveness ratio (ICER) of £49,362/QALY. The ICER remained >£30,000/QALY in scenarios with and without non-fatal outcomes or increased drug costs, and under differing assumptions about the duration of QOF benefit following its hypothetical discontinuation. The ICER for continuing the programme fell below £30,000/QALY when QOF incentive payments were 36% lower (while preserving QOF mortality benefits), and in scenarios where the QOF resulted in substantial reductions in health-care spending or non-fatal cardiovascular disease events. Continuing the QOF was cost-effective in 18%, 3% and 0% of probabilistic sensitivity analysis iterations using thresholds of £30,000/QALY, £20,000/QALY and £13,000/QALY, respectively. Compared to stopping the QOF and returning all associated incentive payments to the National Health Service, continuing the QOF is not cost-effective. To improve population health efficiently, the UK should redesign the QOF or pursue alternative interventions.

X Demographics

X Demographics

The data shown below were collected from the profiles of 63 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 105 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 16%
Researcher 15 14%
Student > Bachelor 13 12%
Other 9 9%
Student > Ph. D. Student 8 8%
Other 17 16%
Unknown 26 25%
Readers by discipline Count As %
Medicine and Dentistry 17 16%
Economics, Econometrics and Finance 15 14%
Nursing and Health Professions 14 13%
Social Sciences 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 18 17%
Unknown 31 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2021.
All research outputs
#1,059,604
of 24,246,771 outputs
Outputs from BMC Medicine
#744
of 3,722 outputs
Outputs of similar age
#23,300
of 338,528 outputs
Outputs of similar age from BMC Medicine
#20
of 69 outputs
Altmetric has tracked 24,246,771 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,722 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,528 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.